Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from VISEN Pharmaceuticals ( (HK:2561) ).
VISEN Pharmaceuticals has appointed Mr. Lu Ying as its new Chief Financial Officer, effective October 13, 2025. Mr. Lu brings over 19 years of financial management experience, having previously served in key financial roles at VivaVision Biotech Limited, Allergan Information Consulting, and Bayer A.G. His extensive background in corporate finance, investor relations, and strategic planning is expected to enhance VISEN Pharmaceuticals’ financial operations and strengthen its industry positioning.
The most recent analyst rating on (HK:2561) stock is a Hold with a HK$41.00 price target. To see the full list of analyst forecasts on VISEN Pharmaceuticals stock, see the HK:2561 Stock Forecast page.
More about VISEN Pharmaceuticals
VISEN Pharmaceuticals is a company incorporated in the Cayman Islands, focusing on the pharmaceutical industry. It is involved in developing and providing innovative therapies, with a market focus that includes ocular diseases.
Average Trading Volume: 44,479
Technical Sentiment Signal: Strong Sell
Current Market Cap: HK$4.73B
See more data about 2561 stock on TipRanks’ Stock Analysis page.